Abstract
31
ATP and the free energy change of ATP-hydrolysis DG were measured using P nuclear magnetic resonance spectroscopy. Results: ATP Ž . Ž . At low concentrations 0.01 to 1.0 mmolrL NO increased CF only; at higher concentrations 1 to 100 mmolrL CF remained elevated and LVDP was significantly reduced. Onset and offset of changes in LVDP occurred always within 2 to 5 s after start and cessation of Ž . NO infusion. Contractile dysfunction was significantly correlated to a pronounced increase in adenosine formation ) 70-fold , a Ž . Ž . significant decrease in myocardial PCr y78% , ATP y25% and a decrease in DG from y61.76 kJrmol to y50.75 kJrmol. This ATP Ž . was paralleled by a significant decrease in myocardial oxygen consumption y65% and a tenfold increase in lactate production. Ž . Coronary vasodilation NO: 0.001 to 1.0 mmolrL significantly correlated with the increase in cGMP release, whereas at negative Ž . inotropic concentrations NO: 10 to 100 mmolrL a clear quantitative and kinetic dissociation between NO-induced changes in cGMP and LVDP was observed. Contractile dysfunction was not related to cardiac release of norepinephrine. Conclusions: In the isolated heart NO can potently depress myocardial energy generation thus being an effective modulator of cardiac contractility. This effect of NO may be of pathophysiological significance in cardiac muscle disorders in vivo. q 1997 Elsevier Science B.V.
Introduction

Ž .
Nitric oxide NO has been demonstrated to modulate systolic and diastolic left ventricular function both in w x w x experimental 1-8 and clinical settings 9-12 . Recently, it has been hypothesized that NO accounts, at least in part, for the myocardial dysfunction associated with a variety of heart muscle disorders such as dilated cardiomyopathy, ( )w x challenged in later experiments 8, [16] [17] [18] [19] . In electrically stimulated adult rat ventricular myocytes NO has been demonstrated to blunt the inotropic effect of the b-adrenergic agonist isoproterenol suggesting that NO might reguw x late contractile function via an anti-adrenergic effect 20 . Recently, it has been postulated that NO inhibits myocarw x dial creatine kinase 21 . Thus, up to now it is not clear whether NO induced contractile disfunction is mediated exclusively by cGMP or if other targets within the cardiomyocytes are affected by NO. Due to its radical nature and extraordinarily high affinity to hemoproteins it is also tempting to speculate that NO affects key enzymes of the mitochondrial electron transport chain thereby directly modulating oxidative phosphorylation and myocardial contraction.
In order to test this hypothesis, we characterized both kinetically and quantitatively the NO-induced changes of cardiac function and of myocardial energy status in the isolated heart. Ž via the pulmonary artery with a polyethylene catheter 1.2 . mm outer diameter, 7 cm length . The tip of the catheter was placed approximately 2 cm below the apex of the heart to permit an optimal drainage of the right ventricle. The mitral valve was cut to prevent fluid accumulation in the left ventricle. After completion of the experimental preparation, the heart was placed in a water jacketed chamber at 378C and allowed to equilibrate for 30 min.
Methods
Preparation of isolated hearts
Cardiac and coronary dynamics
Ž .
Coronary flow CF was measured two centimeters above the orifice of the coronary vessels using an electro-Ž magnetic flow probe SP2202, Statham, Oxnard, CA, . USA . For isovolumetric measurement of left ventricular Ž function, a latex balloon size 4, Hugo Sachs Elektronik . KG, March, Germany was introduced into the left ventricle via the cut mitral valve, which was fixed directly on a stainless steel cannula connected to a pressure transducer Ž . Gould P23, Cleveland, OH, USA . The hearts were paced via the right ventricle at a constant rate 15% above the Ž . further study only when the following criteria were met: i basal coronary flow with no balloon inside was less than 7 Ž . mLrmin, ii maximal coronary flow during reactive hyperemia after a transient 20 s coronary occlusion was at Ž . least 200% of the initial value, and iii LVDP at baseline was greater than 50 mmHg. About 25% of hearts were rejected from further study because not all of these criteria were fulfilled.
After termination of the experiments, the hearts were weighed after blotting the endo-and epicardial surface with a paper towel.
Preparation of nitric oxide standards
A concentration response curve for the cardiac dynamic effects of NO was derived by intracoronary infusion of standards of authentic NO. Standards of aqueous NO w x solution were prepared as previously described 22 . Briefly, NO was dissolved in deoxygenated purified water kept under argon atmosphere. Concentration of NO solutions were routinely determined using the oxyhemoglobinw x assay 23,24 . NO-solutions could be prepared reliably and reproducibly as assessed by low variability of determined Ž . concentrations coefficient of variance 3.4%; n s 12 . NO solutions were kept in gas-tight syringes mounted in a Ž . precision infusion pump Infors AG, Basel, Switzerland and connected to a high performance liquid chromatogra-Ž . phy HPLC steel cannula, which was placed in the aortic inflow line directly in front of the ostium of the coronary arteries in order to limit destruction of NO during its Ž . transport to the tissue stability of NO solution up to 6 h . 31 Phosphorus nuclear magnetic resonance spectroscopy Ž 31 . P-NMR spectra were acquired on an AMX400 WB Ž . pulsed Fourier transform NMR spectrometer Bruker cou-Ž . pled to a 9.4 Tesla superconducting magnet Spectrospin Ž and equipped with a sensitive 20 mm probe-head Fraun-. hofer Institute, St. Ingbert, Germany as described previw x 31 ously 26 . In brief, partially saturated P spectra were accumulated using a radiofrequency pulse width of 58 ms, resulting in a 708 tilt angle, 2k data points in the time domain and a pulse interval of 3 s. Spectra were a result of 128 scans except in the kinetic studies where the number of scans was reduced to 16 scans. Spectra were processed Ž . Ž . using software NMR1 by Tripos St. Louis, USA . Zero Ž filling to 4k and exponential multiplication of the data 5 . Hz line broadening was followed by Fourier transformation, automatic phasing and baseline correction. Manual interactive integration was employed for phosphocreatine Ž . Ž . PCr and adenosine triphosphate ATP and the PCrrATP-ratio was calculated. A curve-fitting routine was used for the integration of the cytosolic P peak, which i partially overlapped with the extracellular P resonance. rmol; R is the gas constant, T is temperature.
Measurement of adenosine
Measurement of cGMP
Measurement of cGMP was performed according to a standard procedure from our laboratory, as previously w x described 22 . Samples of coronary effluent perfusate Ž were passed over Sep-Pak C18 cartridges Waters, Es-. chborn, Germany that had been pretreated with 3 mL Ž . methanol, 2 mL isopropanol 40% v:v and 3 = 2 mL Ž . distilled water, followed by 2 mL KH PO 0.01 molrL . 2 4 Absorbed cGMP was eluted with 2 mL isopropanol and evaporated to dryness. Capacity and reproducibility of the separation procedure was tested with cGMP-standards yielding more than 80% recovery of cGMP. Data of cGMP release were not corrected for losses occurring during the sample purification. Cyclic GMP was determined with a Ž commercially available radioimmunoassay RPA 525, . Amersham, Braunschweig, Germany . Radioactivity of the Ž X w x tracer cGMP-2 -O-succinyl-3-125 iodotyrosine methyl es-. Ž ter was measured by a gamma scintillation counter Model . 05301, Hewlett Packard, Boston, MA, USA and compared to a standard calibration curve.
Measurement of norepinephrine
Ž
. Coronary effluent perfusate 10 mL was sampled into Ž ice-cold tubes containing Na-EGTA ethylene glycol-Ž .
X X bis b-aminoethyl ether N,N,N ,N -tetraacetic acid; final . Ž concentration: 180 mgrL and glutathione 140 mgrL, . Ž . Chromsystems, Munich, Germany . Norepinephrine NE was preconcentrated via solid phase extraction in 2 mL fractions given on cartridges containing aluminium oxide Ž . Ž Al O together with 500 mL of alkaline TRIS buffer pH 2 3 . 8.6 and 50 mL of the internal standard dihydroxybenzy-Ž lamine DHBA, 10 ngrmL, Chromsystems, Munich, Ger-. many and thereafter desorbed with 120 mL of perchloric Ž . acid containing buffer pH 3.0 with a recovery ranging from 70% to 80%. Quantification of NE was accomplished w x as described previously 28 . Briefly, an electrochemical detector was connected to a reversed-phase high perfor-Ž mance liquid chromatography system R4A Chromatopac . Nucleosil-C18 column, Waters, Eschborn, Germany using Ž . isocratic elution 1 mLrmin, 388C with a mobile phase Ž composed of 0.8 g octansulfonic acid Fluka, Buchs, . Ž Switzerland , 1.94 mL dibutylamine reagent D4, Waters, . Eschborn, Germany , 8.2 g sodium acetate, 8.42 g carbomonohydrate, 0.074 g sodium-EDTA, 100 mL methanol Ž . all Merck, Darmstadt, Germany , all added to a final Ž . volume of 2000 mL pH s 4.5 . Using this setup, a detection limit of 11 pmolrL and a coefficient of variance of less than 5% was achieved.
Statistics
Results are expressed as means " standard error of the Ž . mean SEM . Statistical significance between means was tested using a one-way analysis of variance, followed by a least significant difference post-hoc test where appropriate. A p -0.05 was considered significant. Linear regressions were calculated using the method of least squares. Data processing was performed using the SPSS w software pack-Ž . age release 5.0.1, SPSS Inc., Chicago, IL, USA .
Results
Effects of nitric oxide on cardiac function
The cardiac and coronary dynamic parameters at baseline and at the different concentrations of NO are given. NO infused into the coronary circulation significantly increased CF and decreased coronary resistance in a concen-Ž . tration-dependent manner Fig. 1 . In the range of 10 nmolrL to 1 mmolrL, there was no effect on LVDP or d Prdt . However, a further increase in the intracoro- .
NO 10
to 10 molrL were infused into the coronary circulation of isolated constant-pressure perfused guinea pig hearts. ) p-0.05 versus Ž . control, a p-0.05 versus 1 mmolrL NO ns 7-11 .
Effects of nitric oxide on myocardial energy status
At baseline the release of adenosine into the coronary Ž . circulation amounted to 129 " 39 pmolrmin n s 6 . At concentrations of 1 nmolrL to 1 mmolrL NO did not significantly affect adenosine release from isolated hearts. Only at the negative inotropic concentrations NO increased concentration-dependently the release of adenosine from isolated hearts, which at the maximum was 70-fold above Ž . control see Fig. 4 . The coronary venous concentration of adenosine increased from 21 " 7 to 742 " 89 nmolrL. A Ž significant correlation was found between NO-induced 1 . to 100 mmolrL increase in adenosine release and de-Ž crease in LVDP adenosine concentration: r s 0.79, . adenosine release rate: r s 0.75, both p -0.0001 . In Ž . control experiments infusion of adenosine 10 mmolrL Ž . significantly increased CF 17 " 2 mLrmin , but did not Ž . affect LVDP 68 " 4 mmHg, n s 4 , excluding the possibility that the NO-induced decrease in LVDP is mediated Ž . by adenosine itself see inset Fig. 4 . In order to further assess the effects of NO on myocardial energy status, we quantified cardiac release of lactate into the coronary venous effluent. Under baseline conditions lactate levels amounted to 14 " 3 mmolrL. During infusion of NO at Ž . the highest concentration 100 mmolrL, n s 4 lactate significantly increased to 112 " 5 mmolrL. In addition to cardiac release of adenosine the parameters of myocardial energy status PCr, ATP, PCrrATP-ratio, Ž ADP, pH and DG free energy change of ATP-hydrol-
ysis were determined by means of P NMR spectroscopy Ž . in a separate set of experiments n s 4 at control and during infusion of NO at the concentrations which elicited Ž . maximal coronary vasodilation 1 mmolrL and maximal Ž . depression of LVDP 100 mmolrL . These results are summarized in Fig. 5 . No considerable changes in parameters of myocardial energy status were detected at 1 mmolrL NO as compared to control conditions. However, at 100 mmolrL of NO there was a decrease in LVDP accompanied by a 60% decrease in MVO , a substantial increase in 
Effects of nitric oxide on cyclic GMP
Basal release of cGMP into the coronary circulation of Ž . isolated hearts amounted to 360 " 76 fmolrmin n s 7 . Ž . isolated constant-pressure perfused guinea pig hearts ns6 . At concentrations of 1 nmolrL to 1 mmolrL NO significantly increased cGMP release from isolated guinea pig Ž . hearts see Fig. 6 . This increase does not merely reflect Ž . 
Effect of nitric oxide on coronary Õenous pH and release of norepinephrine and CK
At baseline norepinephrine was released into the coro-Ž . nary circulation at a rate of 24.5 " 8.6 pmolrmin n s 5 .
Ž . Infusion of NO 0.001 to 100 mmolrL did not alter norepinephrine release from isolated hearts. When de-Ž . sipramine 0.5 mmolrL was infused to deplete endogenous stores via inhibition of released norepinephrine, a small but not significant decrease in CF from 7.1 to 5.3 mLrmin, in LVDP from 78 to 64 mmHg, and in d Prdt max Ž . from 1243 to 900 mmHgrs n s 2 was seen. Infusion of Ž . NO 1 to 100 mmolrL following 60 min after start of desipramine application increased CF and decreased LVDP to a similar extent as seen without desipramine, excluding a significant interaction of NO-induced changes in LVDP and cardiac norepinephrine.
To assess the cellular integrity of cardiomyocytes and other cardiac cells during NO infusions the release rate of CK into the coronary venous effluent perfusate was measured. At baseline, CK activity was 39 " 9 mUrmin and did not significantly change over the entire NO concentra-Ž tion range infused 100 mmolrL NO: 29 " 3 mUrmin . CK .At baseline, coronary venous pH was 7.32 " 0.05 and Ž . Ž . during NO infusion 100 mmolrL 7.31 " 0.05 p s n.s. .
Discussion
The most important finding of the present study is that in the isolated heart authentic NO can potently depress myocardial energy generation and thus induce contractile dysfunction. NO affects cardiac contractility with extremely rapid kinetics suggesting that this NO-mediated mechanism may play an important role in the regulation of myocardial function under pathophysiological conditions in vivo.
NO and myocardial energy status
The myocardium depends almost exclusively on immediate energy supply by the oxidative mitochondrial w x metabolism 29 . Thus, the matching of energy supply to demand is of fundamental importance for cardiac function. In the present study, NO induced a reversible reduction in both cardiac oxygen consumption and myocardial function. Adenosine is considered to be a sensitive marker for any imbalance between ATP supply and demand, most likely due to the close coupling of adenosine formation to free w x cytosolic AMP and thus the cardiac energy status 25,30 . Accordingly, the NO induced reduction of cardiac contractility was paralleled by a massive, concentration-dependent release of adenosine in our study. Notably, exogenous adenosine infused at comparable concentrations selectively dilated coronary arteries without affecting LVDP, suggesting that the NO induced contractile dysfunction is not mediated by this nucleoside.
Using 31 P-NMR determination of cytosolic concentrations of PCr, ATP, P and the intracellular pH allows to i calculate both the free cytosolic ADP concentration and the free energy change of ATP hydrolysis. This parameter reflects precisely the energy set free during the hydrolysis of ATP to ADP and thus is an index of the myocardial w x energy supply-to-demand ratio 29 . In principle, mitochondrial oxidative energy generation may be impaired by insufficient oxygen supply, or a lack of reducing equivalents, ADP and P . Blockade of the electron transport i chain would have a similar effect. Given the more than 100% increase in coronary flow during infusion of NO, a decrease in cardiac oxygen supply as a cause for the myocardial dysfunction can be excluded in the present study. A lack of ADP or P is equally unlikely, given the i increase of these parameters during 100 mmolrL NO.
Another possible explanation for the observed reduction of cardiac contractility could be opening of intracoronary shunts at higher concentrations of NO similar to the effect seen at high doses of other directly relaxing substances such as papaverine or calcium channel openers. Relevant opening of coronary shunt vessels should result in a considerable decrease in coronary resistance in parallel to a decrease in cardiac contractility. In the present study, coronary resistance decreased over a concentration range . of NO 1 mmolrL to 1 mmolrL that had no effect on myocardial performance. The dose dependent decrease in LVDP at higher concentrations of NO was, however, not accompanied by a further decrease in coronary resistance. Therefore, it appears highly unlikely that at least under our experimental conditions NO reduces myocardial contractility via shunting of coronary perfusate.
In a previous study, a selective decrease in intracellular ATP and a non selective decrease in phosphocreatine were observed in response to an inotropic challenge with intracoronary calcium in isolated rat hearts exposed to the NO w x donor S-nitrosoacetylcysteine 21 . The authors concluded that NO impaired myocardial creatine kinase thereby limiting energy transfer from phosphocreatine to ATP which could eventually lead to a decrease in cardiac contractility w x 21 . It is, however, also conceivable that these results may be explained by inhibition of mitochondrial oxidative phosphorylation, e.g. due to blockade of the electron transport chain.
In the present study, a decrease in both intracellular ATP and PCr and a massive release of adenosine was observed in parallel to the reduction of cardiac oxygen consumption and contractility. These data imply that myocardial energy generation is impaired at the mitochondrial level. While mitochondria are an important cellular source of oxygen derived radicals, they also represent a preferred w x target of free radical attack 31,32 . There is an increasing experimental evidence that NO or its related compounds, such as peroxynitrite or nitrosothiols, interfere with the heme enzymes of the mitochondrial electron transport chain leading to insufficient myocardial energy generation w x 18,31 . Moreover, the effects of NO on oxidative capacity in isolated mitochondria appear to depend critically not only on the amount of NO, but also on the concentration of oxygen, superoxide anions, peroxynitrite, on the substrate Ž . w x used e.g., malate, succinate, or ascorbate 33-37 , and on w x the presence or absence of ATP 36 . In those experiments on isolated mitochondria, the kinetics in onset and offset of the inhibition of mitochondrial respiration were rapid, i.e., below or within minutes depending on the experimental conditions. Thus, both in the isolated mitochondria as well as in our preparation, the NO related effects on energy generation are rapid and reversible. In line with the present experimental data it is of interest that endothelium derived NO has been shown to modulate left ventricular systolic w x and diastolic function in healthy humans 12 . If these preliminary findings are confirmed, the NO mediated reduction in myocardial energy generation as demonstrated in the present study may well be of clinical relevance.
NO and cGMP
Many of the biological effects of NO, in particular smooth muscle relaxation, are mediated by the second Ž w x. messenger cGMP reviewed by 38-40 . In accordance with previous work, the NO induced coronary vasodilation is most likely explained by an activation of soluble guanylyl cyclase within the smooth muscle, as indicated by the parallel increase in coronary flow and coronary venous cGMP concentration at the vasodilatory effective NO conw x centrations, i.e., 10 nmolrL to 1 mmolrL 22, 41 . It has been assumed that cGMP modulates myocardial contractility via inhibition of the L-type calcium channel current w x 42 . In line with this concept, the NO related reduction in contraction of isolated cardiomyocytes was blunted in the presence of the guanylyl cyclase inhibitor methylene blue w x 43 , and in solubilized tissue of left ventricular wall from rat hearts cGMP content increased after induction of myw x ocardial NO synthase 1 . In carbachol-stimulated carw x diomyocytes isolated from guinea pigs 17 , in isoprotew x renol-stimulated rat hearts 44 , and in isolated electrically w x stimulated ferret papillary muscle 16 no direct correlation between changes in cardiac contractility and cGMP formation were observed. By contrast, in rat ventricular myocytes and in isolated human papillary muscles a probably cGMP mediated light increase in contractile response to w x NO-donors has been described 19,45 . This item has become even more complicated by the very recent finding of a bi-directional response of contractility in isolated cat papillary muscles exposed to different types of NO donors, w x which at least in part appeared to be cGMP-mediated 8 . Based on these contradictory findings, the role of cGMP as a second messenger for the NO induced changes in my-Ž ocardial contractility has been questioned recently for w x. review see 15 . However, up to now quantitative and kinetic data on NO-induced release of cardiac cGMP and their correlation to changes in cardiac function in isolated hearts have been missing. In the present study, NO did not further alter cardiac cGMP release within its negative inotropic concentration range. Consequently, no correlation between NO-induced changes in cGMP and LVDP was found. This effect might be caused by a generalized down regulation of cardiac energy generation during NO Ž . infusion 100 mmolrL , which would have prevented a further increase of guanylyl cyclase activity. Nevertheless, a clear dissociation between the kinetics of reversal of changes in cGMP release and LVDP after cessation of NO infusion was observed, indicating that LV function was already restored although cGMP was still elevated. Moreover, high doses of the stable analogue 8-bromo-cGMP failed to mimic NO induced depression of cardiac contractility. Taken together, these findings suggest that NO induced contractile dysfunction cannot be exclusively explained by an enhanced stimulation of guanylyl cyclase in our experimental model.
NO and norepinephrine
In electrically stimulated adult rat ventricular myocytes NO has been demonstrated to blunt the inotropic effect of w x the b-adrenergic agonist isoproterenol 20 suggesting that NO might modulate catecholaminergic myocardial effects. In the present study NO did not alter cardiac NE release. Moreover, NO induced changes of cardiac function were almost identical in the absence and presence of desipramine, which depleted neuronal NE stores via blockage of NE reuptake, as indicated by a decrease of CF in the respective control experiments. Thus, the NO-induced reduction of contractility at least in isolated guinea pig hearts appears not to be mediated by an altered release or reuptake of cardiac NE.
Critique of methods and study limitations
In the present study, aqueous solutions of authentic NO standards were chosen to investigate the effects of NO on cardiac function in an isolated heart preparation over a wide concentration range. These standards were prepared with a reliable reproducibility and offer several advantages compared to NO generated from pharmacological NO Ž . donors: 1 side effects were avoided, which could be related to the decomposition product of drugs following NO generation, such as organic nitrates or sodium nitrow x Ž . prusside 46 . 2 Because of the rapid inactivation of NO w x within the heart 22 , the present protocol allows to measure exactly the kinetics of the NO induced changes in cardiac function without being hampered by slow on and off responses, due to bioactivation of NO donors, diffusion Ž . problems, or washout phenomena of these drugs. 3 In the present study the effects of NO on cardiac function were elicited not by its stable metabolites nitrite and nitrate, as indicated by our control experiments. This does not necessarily mean that the effects observed following intracoronary infusion of authentic NO are exclusively mediated by NO itself. Intramyocardial conversion along its route of diffusion to cardiomyocytes resulting in NO-related compounds such as nitrosothiols or peroxynitrite may at least in part contribute to the NO-induced contractile dysfunction.
A possible drawback of our experimental approach is that we cannot exactly determine the proportion of bioactive NO at the site of the cardiomyocytes. Kinetic modeling predicts that a major part of the NO in the vasculature w x is scavanged along its route to the interstitium 47 . In our study, even at the highest intracoronary concentrations of NO no long term toxic effects were present as evidenced Ž . by i the rapid recovery after cessation of NO infusion Ž . and ii the lack of cell damage measured as release of CK into the coronary effluent perfusate. However, the amount of bioactive NO necessary to modulate myocardial energy generation at the intracellular level in vivo remains to be determined. In this context, the very recent immunohistochemical localization of a mitochondrial NO synthase in w x rat hearts 48 is of particular interest since the NO produced within the mitochondria may control myocardial energy generation directly at its site of production.
Implications for future studies
The direct impact of NO on myocardial energy generation may be an important feature of NO under in vivo conditions, as this suggests that cardiac endothelial and endocardial cells as well as smooth muscle cells and cardiomyocytes may effectively modulate cardiac contractility via the generation and release of NO. Further in vivo studies devoted to the hypothesis that NO from different sources may influence mitochondrial energy generation and thus LV function in vivo are warranted, as this mechanism may offer a new therapeutic target in a variety of heart muscle disorders.
